IRIDEX CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRIDEX Corporation on October 10, 2011. The filing reports significant changes in executive leadership and the execution of new compensatory agreements effective as of the report date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms and severance arrangements.
Material Changes
- Resignation of CEO: Theodore A. Boutacoff resigned as President, Chief Executive Officer, and Board member effective October 10, 2011.
- Appointment of New CEO: Dominik Beck, Ph.D., was appointed President, Chief Executive Officer, and Board member effective October 10, 2011.
- Role Transition: Theodore A. Boutacoff was appointed Chief Technology Officer (CTO) effective October 10, 2011.
Compensation, Outlook, and Risks
New CEO Compensation (Dr. Beck):
- Annualized base salary: $300,000.
- Equity: 135,000 stock options (4-year vesting) and 75,000 restricted stock units (RSUs).
- Relocation: Up to $65,000 reimbursement if relocated within 12 months.
- Severance (Change of Control): 12 months' base salary, full equity vesting acceleration, and 12 months of COBRA benefits.
- Severance (Outside Change of Control): 6 to 12 months' base salary depending on tenure, plus 12 months of COBRA benefits.
Outgoing CEO/CTO Compensation (Mr. Boutacoff):
- Annualized base salary: $210,000.
- Equity: Extension of post-termination exercise periods; full vesting of unvested awards if employed through February 10, 2013.
- Severance (Involuntary/Death/Disability): Lump sum equal to salary through February 10, 2013, COBRA benefits through that date, and full equity vesting acceleration.
Outlook and Risks: The filing contains no forward-looking financial guidance or specific risk factors beyond the standard contingencies related to executive termination and change of control provisions.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for Dr. Beck's 135,000 options and 75,000 RSUs in the attached Employment Agreement (Exhibit 99.1).
- Confirm the specific definitions of "Good Reason," "Cause," and "Change of Control" in the agreements to understand severance triggers.
- Review the press release (Exhibit 99.3) for strategic rationale behind the leadership transition.
- Check subsequent filings for the impact of these compensation changes on the company's stock-based compensation expense.